Global Trends in Carbapenem- and Difficult-to-Treat-Resistance Among World Health Organization Priority Bacterial Pathogens: ATLAS Surveillance Program 2018-2022
The ATLAS global surveillance program collected clinical isolates of Gram-negative priority pathogens from 2018 to 2022. Results showed an increase in carbapenem-resistant Enterobacterales (CRE) detection in APAC, EUR, LATAM, and MEA regions, and a decrease in NA. Annual DTR percentages increased in all five regions. CRE percentages were primarily due to hospital-acquired infections. KPC is, in fact, the most frequent carbapenemase found in both NA and EUR (among the meropenem non-susceptible
Enterobacterales). The study highlights the need for ongoing surveillance to inform treatment strategies and antimicrobial stewardship.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!